Lee's Pharmaceutical Holdings Ltd ($950) - buy or sell? Stock discussion, ideas, forum

Lee's Pharmaceutical Holdings Ltd

Lee's Pharmaceutical Holdings Limited develops, manufactures and sells quality biopharmaceutical products that focus on combating cardiovascular diseases and viral sexually transmitted diseases.

Industry: Pharmaceuticals

Ticker	Exchange	ISIN	Name
$950	HKEx Main Board	KYG5438W1116	Code: 950

Recent news

TAI Ping Carpet International Ltd revenue jumped on 34.8% while EBITDA Margin decreased on 2.8 pp from 9.9% to 7.1%

Vision Fame International Holding Ltd revenue growth accelerated from 2.3% in FY2019 to 405% in FY2020

Kantone Holdings Ltd reports 13.0% EBITDA growth in 2020 and 0.61 pp EBITDA Margin growth from 5.7% to 6.3%

Heng Tai Consumables Group Ltd revenue dropped on 35.5% and EBITDA Margin dropped on 19.0 pp from -27.6% to -46.6%

Yat Sing Holdings Ltd revenue decreased on 8.4% and EBITDA Margin decreased on 2.2 pp from -1.7% to -3.9%

Art Textile Technology International Co Ltd Net Debt / EBITDA surged on 82.8x from 3.9x to 86.8x in 2020 while Revenue dropped on 24.7%

China Zenith Chemical Group Ltd revenue dropped on 39.8% while EBITDA Margin surged on 93.4 pp from -149% to -55.4%

Odella Leather Holdings Ltd revenue returned to growth in FY2020: increased 60.4% vs. 48.6% decline a year earliner

New World Development Co Ltd Net Income dropped on 85.3% and Revenue dropped on 23.1%

NWS Holdings Ltd reports 80.3% Net Income decline in 2020 and 3.4% Revenue decline

Twit about 950 stock

Share your investment idea or question on Lee's Pharmaceutical Holdings Ltd stock:

Latest twits on Lee's Pharmaceutical Holdings Ltd (950)

No twits yet. Be the first to post!

Have a question about 950? Ask and other investors will be eager to help you.

Have an idea about 950? Share it with other investors.

Lee's Pharmaceutical Holdings Ltd news

23/03/2017 Lee's Pharmaceutical Holdings Ltd EBITDA Margin dropped on 37.9 pp from 37.9% to in 2016

23/03/2016 Lee's Pharmaceutical Holdings Ltd CAPEX jumped on 255% in 2015 while Revenue decreased on 3.5%

02/04/2015 Lee's Pharmaceutical Holdings Ltd's three year revenue growth was 33.7% and EBITDA growth was 32.9% per year

Lee's Pharmaceutical Holdings Ltd stock price chart

Lee's Pharmaceutical Holdings Ltd financials

mln. HKD	FY2010	FY2011	FY2012

Revenue	255.8	399.7	534.3
EBITDA	77.601	109.5	146.9
Net income	58.026	83.906	113.8
CAPEX	7.345	33.947	99.215
Debt	18.256	18.551	32.365
Cash	120.1	134.5	333.9

Lee's Pharmaceutical Holdings Ltd news

About Lee's Pharmaceutical Holdings Ltd

Lee's Pharmaceutical Holdings Limited develops, manufactures and sells quality biopharmaceutical products that focus on combating cardiovascular diseases and viral sexually transmitted diseases.